Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.

ABSTRACT:

Background

Estimating patient attrition across lines of treatment (i.e. the probability that upon treatment failure the patient will not be able to receive a subsequent treatment) may be a valuable tool for optimizing treatment sequencing. We sought to describe the first-to-second-line attrition rate and factors associated with attrition in a real-world cohort of patients with metastatic breast cancer.

Methods

The Gruppo Italiano Mammella (GIM)14/BIO-META (NCT02284581) is an ongoing, ambispective observational multicenter study enrolling patients with metastatic breast cancer receiving first-line therapy. In patients experiencing disease progression, attrition was defined as no further anticancer treatment and death within 6 months from the end of first-line therapy. The att

SUBMITTER: Blondeaux E 

PROVIDER: S-EPMC11794064 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature